ストックスクリーナーアプリを入手
16.97
4.11%
0.67
アフターアワーズ：
17.00
0.03
+0.18%
前日終値:
$16.30
開ける：
$16.51
24時間の取引高:
1.68M
Relative Volume:
1.45
時価総額：
$1.75B
収益：
$71.78M
当期純損益:
$-295.28M
株価収益率:
-5.3708
EPS:
-3.1597
ネットキャッシュフロー:
$-271.85M
1週間 パフォーマンス:
+8.78%
1か月 パフォーマンス:
+12.83%
6か月 パフォーマンス:
+63.96%
1年 パフォーマンス:
+72.81%
1日の値動き範囲:
$16.36
$17.11
1週間の範囲:
$15.47
$17.11
52週間の値動き範囲:
$8.195
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
名前
Nurix Therapeutics Inc
セクター
電話
(415) 660-5320
住所
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
16.97 | 1.69B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-03-17 | 開始されました | Leerink Partners | Market Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-11 | 開始されました | Jefferies | Buy |
| 2024-09-06 | 再開されました | Robert W. Baird | Outperform |
| 2024-07-31 | 開始されました | Truist | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-09 | 開始されました | Barclays | Overweight |
| 2023-02-28 | 開始されました | Oppenheimer | Outperform |
| 2022-10-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-12-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-30 | 再開されました | Piper Sandler | Overweight |
| 2021-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-11-19 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | Stifel | Buy |
すべてを表示
Nurix Therapeutics Inc (NRIX) 最新ニュース
Nurix Therapeutics shares edge higher despite Q1 earnings miss - MSN
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Does Nurix Therapeutics (NRIX) have the potential to rally 85.84% as Wall Street analysts expect? - MSN
Q2 EPS Estimate for Nurix Therapeutics Lifted by Analyst - MarketBeat
NRIX: Lead BTK degrader enters phase III for CLL, with strong efficacy and robust financial runway - TradingView — Track All Markets
NRIX: Lead BTK degrader enters phase III in CLL, with strong efficacy and broad pipeline momentum - TradingView — Track All Markets
A Look At Nurix Therapeutics (NRIX) Valuation After Recent Share Price Weakness - Sahm
(NRIX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Did Sanofi Revenue Expiry and Rising R&D Spend Just Recast Nurix Therapeutics' (NRIX) Investment Narrative? - Yahoo Finance
Does Wall Street Predict an 85.84% Surge for Nurix Therapeutics (NRIX)? - Bitget
Nurix Therapeutics, Inc. (NRIX) reports Q1 loss, lags revenue estimates - MSN
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect? - Yahoo Finance
Growth Report: Can Nurix Therapeutics Inc sustain its profitabilityWeekly Trade Recap & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
HC Wainwright Reaffirms Buy Rating on NRIX with $32 Target | NRI - GuruFocus
Nurix Therapeutics' (NRIX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
How Weaker Q1 Results And Advancing Bexobrutideg Trials At Nurix Therapeutics (NRIX) Have Changed Its Investment Story - Sahm
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Truist Financial Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics Inc reports results for the quarter ended February 28Earnings Summary - TradingView — Track All Markets
Portfolio Recap: Is Nurix Therapeutics Inc undervalued by DCF analysis2026 Year in Review & Safe Capital Growth Plans - baoquankhu1.vn
NRIX: Wells Fargo Adjusts Price Target while Maintaining Overwei - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $28.00 by Analysts at Wells Fargo & Company - MarketBeat
Wells Fargo cuts Nurix stock price target on CLL trial timing - Investing.com
Nurix Therapeutics (NRIX) Heavy Q1 Net Loss Reinforces Bearish Narrative On Profitability - Sahm
Inside Nurix Therapeutics Inc (NRIX): A Comprehensive SWOT Break - GuruFocus
Inside Nurix Therapeutics Inc (NRIX): A Comprehensive SWOT Breakdown - GuruFocus
Nurix Therapeutics (NRIX) Stock Declines Amid Expanding Losses and R&D Investment - mexc.co
NRIX: Needham Reiterates Buy Rating with Target Price of $26.00 - GuruFocus
Nurix Therapeutics (NRIX) Stock: Slides as Losses Widen Despite Pipeline Progress - CoinCentral
Needham & Company LLC Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Nurix Advances NX-5948 Into Phase 3 Head-to-Head Battle in CLL/SLL - TipRanks
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Bitget
Nurix Therapeutics, Inc. (NRIX) Posts Q1 2026 Results - AlphaStreet
Nurix Therapeutics stocks rise 3% despite Q1 miss - Investing.com
Nurix Therapeutics stocks rise 3% despite Q1 miss By Investing.com - Investing.com South Africa
Nurix Therapeutics, Inc. Q1 2026 Financial Results: Continued R&D Investment, Collaboration Revenue, and Key Risk Factors Highlighted in 10-Q Filing - Minichart
Nurix Therapeutics (NRIX) Q1 FY2026 Earnings: EPS -$0.79 (Miss v - GuruFocus
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2026 - marketscreener.com
Nurix Therapeutics Reports Q1 2026 Financial Results and Corporate Update - Minichart
Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
NRIX Reports Lower Q1 Revenue; Focuses on Key Medical Developmen - GuruFocus
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Nurix Therapeutics Fiscal Q1 Loss Widens, Revenue Falls - marketscreener.com
[10-Q] Nurix Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Earnings Flash (NRIX) Nurix Therapeutics Posts Fiscal Q1 Loss $0.79 a Share, vs. FactSet Est of $0.76 Loss - marketscreener.com
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q1 Revenue $6.3M, vs. FactSet Est of $14.3M - marketscreener.com
Nurix Therapeutics 3Q 2026: Revenue $6.25M, EPS $(0.79) — 10-Q Summary - TradingView — Track All Markets
Nurix Therapeutics Q1 loss widens on higher costs - TradingView
NRIX: Q1 2026 saw pipeline progress, higher R&D costs, and a strong cash position amid lower revenue - TradingView — Track All Markets
Nurix Therapeutics Inc (NRIX) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):